Advertisement

AAPS PharmSciTech

, 20:19 | Cite as

Exploring the Nano Spray-Drying Technology as an Innovative Manufacturing Method for Solid Lipid Nanoparticle Dry Powders

  • Krystyna Glaubitt
  • Maurizio Ricci
  • Stefano GiovagnoliEmail author
Research Article
  • 34 Downloads

Abstract

To take advantage of solid-state properties, the nano spray-drying (NSD) technique was investigated as an innovative one-step method to produce solid lipid nanoparticles (SLN) in the form of a dry powder starting from a lipid/leucine O/W emulsion. Compritol was chosen as wall-forming lipid. Rapamycin (Rp) was employed as a model drug to be loaded into SLN. Based on an initial screening, Lutrol F68 was chosen as surfactant and high-shear homogenization as an emulsification method. A two-level fractional factorial design and an extended factorial design were employed to determine critical factors and best preparation conditions. Compritol concentration, l-leucine/lipid ratio, and Lutrol F68 concentration resulted critical. Best conditions granted 51% yield, 3.2 μm l-leucine/SLN particle size, and a SLN population around 150 nm. All samples showed the presence of lipid aggregates. Material loss in the emulsification step was found responsible for SLN aggregation and low yield. The almost quantitative Rp loading increased SLN population span. Replacing compritol with cetyl palmitate produced aggregation of dry powders and SLN. Overall, NSD was found a fast method to produce SLN dry powders. More insightful assessment of the emulsification step and lipid property effects will be critical to the optimization of the NSD process. Hypotheses account for direct coupling of high-pressure homogenization with NSD for future successful development of this promising manufacturing method.

KEY WORDS

Nano spray-drying Solid lipid nanoparticles SLN-leucine particles Dry powder 

Notes

Acknowledgements

This work was partially performed at the University of Perugia Interdepartmental Laboratories of Nanomaterials (L.U.NA.).

Supplementary material

12249_2018_1203_MOESM1_ESM.docx (5 mb)
ESM 1 (DOCX 5140 kb)

References

  1. 1.
    Mehnert W, Mäder K. Solid lipid nanoparticles. Adv Drug Deliv Rev [Internet]. 2012;64:83–101.CrossRefGoogle Scholar
  2. 2.
    Shegokar R, Singh KK, Müller RH. Production & stability of stavudine solid lipid nanoparticles—from lab to industrial scale. Int J Pharm. 2011;416:461–70.CrossRefGoogle Scholar
  3. 3.
    Patil H, Kulkarni V, Majumdar S, Repka MA. Continuous manufacturing of solid lipid nanoparticles by hot melt extrusion. Int J Pharm. 2014;471:153–6.CrossRefGoogle Scholar
  4. 4.
    Radomskasoukharev A. Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59:411–8.CrossRefGoogle Scholar
  5. 5.
    Salminen H, Helgason T, Aulbach S, Kristinsson B, Kristbergsson K, Weiss J. Influence of co-surfactants on crystallization and stability of solid lipid nanoparticles. J Colloid Interface Sci. 2014;426:256–63.CrossRefGoogle Scholar
  6. 6.
    Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59:454–77.CrossRefGoogle Scholar
  7. 7.
    Pietkiewicz J, Sznitowska M, Placzek M. The expulsion of lipophilic drugs from the cores of solid lipid microspheres in diluted suspensions and in concentrates. Int J Pharm. 2006;310:64–71.CrossRefGoogle Scholar
  8. 8.
    Westesen K, Bunjes H. Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int J Pharm. 1995;115:129–31.CrossRefGoogle Scholar
  9. 9.
    Trotta M, Cavalli R, Trotta C, Bussano R, Costa L. Electrospray technique for solid lipid-based particle production. Drug Dev Ind Pharm. 2010;36:431–8.CrossRefGoogle Scholar
  10. 10.
    Campardelli R, Cherain M, Perfetti C, Iorio C, Scognamiglio M, Reverchon E, et al. Lipid nanoparticles production by supercritical fluid assisted emulsion–diffusion. J Supercrit Fluids. 2013;82:34–40.CrossRefGoogle Scholar
  11. 11.
    Chattopahdyay P, Shekunov B, Yim D, Cipolla D, Boyd B, Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system☆. Adv Drug Deliv Rev. 2007;59:444–53.CrossRefGoogle Scholar
  12. 12.
    Freitas C, Müllerä RH. Spray-drying of solid lipid nanoparticles (SLN TM). Eur J Pharm Biopharm. 1998;46:145–51.CrossRefGoogle Scholar
  13. 13.
    Gaspar DP, Serra C, Lino PR, Gonçalves L, Taboada P, Remuñán-López C, et al. Microencapsulated SLN: an innovative strategy for pulmonary protein delivery. Int J Pharm. 2017;516:231–46.CrossRefGoogle Scholar
  14. 14.
    Di Sabatino M, Albertini B, Kett VL, Passerini N. Spray congealed lipid microparticles with high protein loading: preparation and solid state characterisation. Eur J Pharm Sci. 2012;46:346–56.CrossRefGoogle Scholar
  15. 15.
    Cordeiro P, Temtem M, Winters C. Spray congealing: applications in the pharmaceutical industry. Chimica Oggi/Chemistry Today. 2013;31(5):69–72.Google Scholar
  16. 16.
    Wang T, Hu Q, Zhou M, Xue J, Luo Y. Preparation of ultra-fine powders from polysaccharide-coated solid lipid nanoparticles and nanostructured lipid carriers by innovative nano spray drying technology. Int J Pharm. 2016;511:219–22.CrossRefGoogle Scholar
  17. 17.
    Wang T, Hu Q, Zhou M, Xia Y, Nieh M-P, Luo Y. Development of “all natural” layer-by-layer redispersible solid lipid nanoparticles by nano spray drying technology. Eur J Pharm Biopharm. 2016;107:273–85.CrossRefGoogle Scholar
  18. 18.
    Heng D, Lee SH, Ng WK, Tan RB. The nano spray dryer B-90. Expert Opin Drug Deliv [Internet]. 2011;8:965–72 Available from: http://www.tandfonline.com/doi/full/10.1517/17425247.2011.588206.CrossRefGoogle Scholar
  19. 19.
    Schmid K, Arpagaus C, Friess W. Evaluation of the Nano Spray Dryer B-90 for pharmaceutical applications. Pharm Dev Technol. 2011;16:287–94.CrossRefGoogle Scholar
  20. 20.
    Oliveira AM, Guimaraes KL, Cerize NN, Tunussi AS, Poco JG. Nano spray drying as an innovative technology for encapsulating hydrophilic active pharmaceutical ingredients (API). J Nanomed Nanotechnol. 2013;4(6):186.CrossRefGoogle Scholar
  21. 21.
    Derringer G, Suich R. Simultaneous optimization of several response variables. J Qual Technol. 1980;12:214–9.CrossRefGoogle Scholar
  22. 22.
    Mazuryk J, Deptuła T, Polchi A, Gapiński J, Giovagnoli S, Magini A, et al. Rapamycin-loaded solid lipid nanoparticles: morphology and impact of the drug loading on the phase transition between lipid polymorphs. Colloids Surfaces A Physicochem Eng Asp. 2016;502:54–65.CrossRefGoogle Scholar
  23. 23.
    Polchi A, Magini A, Mazuryk J, Tancini B, Gapiński J, Patkowski A, et al. Rapamycin loaded solid lipid nanoparticles as a new tool to deliver mTOR inhibitors: formulation and in vitro characterization. Nano. 2016;6:87.Google Scholar
  24. 24.
    Singh-Joy SD, McLain VC. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol. 2008;27(Suppl. 2):93–128.PubMedGoogle Scholar
  25. 25.
    Pedroso JAB, Zampieri TT, Donato J Jr. Reviewing the effects of l-leucine supplementation in the regulation of food intake, energy balance, and glucose homeostasis. Nutrients. 2015;7(5):3914–37.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical TechnologyMedical University of GdańskGdańskPoland
  2. 2.Department of Pharmaceutical SciencesUniversity of PerugiaPerugiaItaly

Personalised recommendations